BioAge Labs’ lead drug candidate, azelaprag, is in Phase 2 testing in combination with Eli Lilly’s weight management medication Zepbound. The biotech’s oral drug activates a receptor it says can mimic certain biological effects of exercise.
The post Exercise Benefit in a Pill: BioAge Labs Goes Public, Raising More Than $200M for Clinical Trials appeared first on MedCity News.
